CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 1 filers reported holding CONCERT PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $6,682,000 | -21.7% | 479,000 | -4.2% | 0.02% | -23.8% |
| Q1 2017 | $8,530,000 | +629.7% | 500,000 | +340.0% | 0.02% | +600.0% |
| Q4 2016 | $1,169,000 | -77.3% | 113,627 | -77.7% | 0.00% | -76.9% |
| Q2 2014 | $5,152,000 | -24.9% | 510,148 | 0.0% | 0.01% | -31.6% |
| Q1 2014 | $6,861,000 | – | 510,148 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 1,050,124 | $10,312,000 | 3.31% |
| Alambic Investment Management, L.P. | 19,934 | $196,000 | 2.15% |
| INGALLS & SNYDER LLC | 1,363,603 | $13,391,000 | 0.92% |
| ACUTA CAPITAL PARTNERS, LLC | 300,000 | $2,946,000 | 0.80% |
| RA Capital Management | 1,858,474 | $18,250,000 | 0.33% |
| Perceptive Advisors | 2,150,641 | $21,119,000 | 0.31% |
| SPHERA FUNDS MANAGEMENT LTD. | 310,000 | $3,044,000 | 0.30% |
| Eversept Partners, LP | 103,829 | $1,019,601 | 0.23% |
| Opaleye Management Inc. | 100,000 | $982,000 | 0.19% |
| GSA CAPITAL PARTNERS LLP | 58,095 | $570,000 | 0.10% |